Published in Cancers (Basel) on June 21, 2010
The Nrf1 CNC-bZIP protein is regulated by the proteasome and activated by hypoxia. PLoS One (2011) 0.89
Reactive Oxygen Species and Nuclear Factor Erythroid 2-Related Factor 2 Activation in Diabetic Nephropathy: A Hidden Target. J Diabetes Metab (2015) 0.79
Nrf1 and Nrf2 transcription factors regulate androgen receptor transactivation in prostate cancer cells. PLoS One (2014) 0.78
Peroxiredoxin 1 - an antioxidant enzyme in cancer. J Cell Mol Med (2016) 0.75
Repeated ozone exposure exacerbates insulin resistance and activates innate immune response in genetically susceptible mice. Inhal Toxicol (2016) 0.75
Selenium- or Vitamin E-Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT. Cancer Epidemiol Biomarkers Prev (2016) 0.75
HSP90 inhibitor 17-DMAG exerts anticancer effects against gastric cancer cells principally by altering oxidant-antioxidant balance. Oncotarget (2017) 0.75
Proteostasis, oxidative stress and aging. Redox Biol (2017) 0.75
Cell signaling. H2O2, a necessary evil for cell signaling. Science (2006) 7.53
Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med (2005) 5.83
Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res (2008) 5.79
Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J Clin Invest (2006) 4.41
Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res (1994) 4.32
Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-alpha activation. Cell Metab (2005) 3.94
Dual roles of Nrf2 in cancer. Pharmacol Res (2008) 3.41
Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res (1999) 3.41
Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model. Mol Cell Biol (2006) 3.27
Identification of a novel Nrf2-regulated antioxidant response element (ARE) in the mouse NAD(P)H:quinone oxidoreductase 1 gene: reassessment of the ARE consensus sequence. Biochem J (2003) 3.13
Molecular mechanism activating Nrf2-Keap1 pathway in regulation of adaptive response to electrophiles. Free Radic Biol Med (2004) 3.09
Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cell Physiol Biochem (2001) 3.07
Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res (2008) 2.96
Modifying specific cysteines of the electrophile-sensing human Keap1 protein is insufficient to disrupt binding to the Nrf2 domain Neh2. Proc Natl Acad Sci U S A (2005) 2.92
Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes. Oncogene (1998) 2.92
Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Res (2007) 2.54
Nrf2 as a master redox switch in turning on the cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals. Planta Med (2008) 2.48
The thioredoxin system in cancer. Semin Cancer Biol (2006) 2.42
Hypoxia activates NADPH oxidase to increase [ROS]i and [Ca2+]i through the mitochondrial ROS-PKCepsilon signaling axis in pulmonary artery smooth muscle cells. Free Radic Biol Med (2008) 2.35
Impaired expression of glutathione synthetic enzyme genes in mice with targeted deletion of the Nrf2 basic-leucine zipper protein. Biochim Biophys Acta (2000) 2.34
Reactive oxygen species produced by NAD(P)H oxidase inhibit apoptosis in pancreatic cancer cells. J Biol Chem (2004) 2.28
Oxidative stress in prostate cancer. Cancer Lett (2009) 2.28
Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett (2008) 2.28
Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells. Mol Cell (2010) 2.24
Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol Cancer Ther (2010) 2.21
Liver-specific inactivation of the Nrf1 gene in adult mouse leads to nonalcoholic steatohepatitis and hepatic neoplasia. Proc Natl Acad Sci U S A (2005) 2.12
Oxidative and electrophilic stress induces multidrug resistance-associated protein transporters via the nuclear factor-E2-related factor-2 transcriptional pathway. Hepatology (2007) 2.11
Nrf2 signaling: an adaptive response pathway for protection against environmental toxic insults. Mutat Res (2007) 2.10
Redox signaling: hydrogen peroxide as intracellular messenger. Exp Mol Med (1999) 2.09
Distinct roles of thioredoxin in the cytoplasm and in the nucleus. A two-step mechanism of redox regulation of transcription factor NF-kappaB. J Biol Chem (1999) 1.99
Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice. Carcinogenesis (2009) 1.85
Redox-regulated turnover of Nrf2 is determined by at least two separate protein domains, the redox-sensitive Neh2 degron and the redox-insensitive Neh6 degron. J Biol Chem (2004) 1.81
Human prx1 gene is a target of Nrf2 and is up-regulated by hypoxia/reoxygenation: implication to tumor biology. Cancer Res (2007) 1.80
The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res (2008) 1.76
Nrf1 and Nrf2 play distinct roles in activation of antioxidant response element-dependent genes. J Biol Chem (2008) 1.73
NOX5 NAD(P)H oxidase regulates growth and apoptosis in DU 145 prostate cancer cells. Am J Physiol Cell Physiol (2003) 1.73
Nrf1 is targeted to the endoplasmic reticulum membrane by an N-terminal transmembrane domain. Inhibition of nuclear translocation and transacting function. J Biol Chem (2006) 1.69
Increased colonic inflammatory injury and formation of aberrant crypt foci in Nrf2-deficient mice upon dextran sulfate treatment. Int J Cancer (2007) 1.67
Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways. BJU Int (2009) 1.66
The ubiquitin-dependent proteolytic system and other potential targets for the modulation of nuclear factor-kB (NF-kB). Curr Drug Targets (2000) 1.61
Nrf1 and Nrf2 regulate rat glutamate-cysteine ligase catalytic subunit transcription indirectly via NF-kappaB and AP-1. Mol Cell Biol (2005) 1.61
High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. Am J Surg Pathol (2004) 1.61
Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res (2007) 1.61
Thioredoxin signaling as a target for cancer therapy. Curr Opin Pharmacol (2007) 1.59
Functional variant of manganese superoxide dismutase (SOD2 V16A) polymorphism is associated with prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer study. Cancer Epidemiol Biomarkers Prev (2007) 1.58
The 26 S proteasome: from basic mechanisms to drug targeting. J Biol Chem (2009) 1.55
The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am (1999) 1.55
Androgen receptor roles in spermatogenesis and fertility: lessons from testicular cell-specific androgen receptor knockout mice. Endocr Rev (2009) 1.55
The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis. Oncogene (2008) 1.50
Dietary chemopreventive compounds and ARE/EpRE signaling. Free Radic Biol Med (2004) 1.50
Human small Maf proteins form heterodimers with CNC family transcription factors and recognize the NF-E2 motif. Oncogene (1997) 1.50
The dual functions of thiol-based peroxidases in H2O2 scavenging and signaling. Antioxid Redox Signal (2008) 1.49
Role of Nrf1 in antioxidant response element-mediated gene expression and beyond. Toxicol Appl Pharmacol (2009) 1.49
Superoxide radical: controversies, contradictions, and paradoxes. Proc Soc Exp Biol Med (1995) 1.47
Interaction of the CNC-bZIP factor TCF11/LCR-F1/Nrf1 with MafG: binding-site selection and regulation of transcription. Nucleic Acids Res (1998) 1.45
Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails. Oncogene (2010) 1.43
Nrf1 is critical for redox balance and survival of liver cells during development. Mol Cell Biol (2003) 1.42
Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings. Urology (2002) 1.37
Reactive oxygen species as double-edged swords in cellular processes: low-dose cell signaling versus high-dose toxicity. Hum Exp Toxicol (2002) 1.37
Negative regulation of the Nrf1 transcription factor by its N-terminal domain is independent of Keap1: Nrf1, but not Nrf2, is targeted to the endoplasmic reticulum. Biochem J (2006) 1.37
Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev Urol (2007) 1.36
The role of metallothionein in oncogenesis and cancer prognosis. Prog Histochem Cytochem (2008) 1.36
Androgenic regulation of oxidative stress in the rat prostate: involvement of NAD(P)H oxidases and antioxidant defense machinery during prostatic involution and regrowth. Am J Pathol (2003) 1.33
Hypoxia in prostate cancer: a powerful shield against tumour destruction? Cancer Treat Rev (2008) 1.30
Irreversible oxidation of the active-site cysteine of peroxiredoxin to cysteine sulfonic acid for enhanced molecular chaperone activity. J Biol Chem (2008) 1.27
Peroxiredoxin I expression in oral cancer: a potential new tumor marker. Cancer Lett (2000) 1.26
Increased expression of Nrf2/ARE-dependent anti-oxidant proteins in tamoxifen-resistant breast cancer cells. Free Radic Biol Med (2008) 1.24
Functional characterization of transcription regulators that interact with the electrophile response element. Biochem Biophys Res Commun (2001) 1.23
Nuclear factor-E2-related factor-1 mediates ascorbic acid induction of osterix expression via interaction with antioxidant-responsive element in bone cells. J Biol Chem (2007) 1.23
Activation of the neutrophil respiratory burst oxidase. J Infect Dis (1999) 1.23
Control of IkappaBalpha proteolysis by the ubiquitin-proteasome pathway. Biochimie (2001) 1.21
The p65 isoform of Nrf1 is a dominant negative inhibitor of ARE-mediated transcription. J Biol Chem (2007) 1.17
Peroxiredoxin I expression in human thyroid tumors. Cancer Lett (1999) 1.17
Enhanced expression of NADPH oxidase Nox4 in human gliomas and its roles in cell proliferation and survival. Int J Cancer (2008) 1.16
Peroxiredoxin 1 interacts with androgen receptor and enhances its transactivation. Cancer Res (2007) 1.15
The NHB1 (N-terminal homology box 1) sequence in transcription factor Nrf1 is required to anchor it to the endoplasmic reticulum and also to enable its asparagine-glycosylation. Biochem J (2007) 1.14
Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease. Urol Oncol (2009) 1.14
Nrf2 transcriptionally activates the mafG gene through an antioxidant response element. J Biol Chem (2004) 1.12
Nuclear and cytoplasmic peroxiredoxin-1 differentially regulate NF-kappaB activities. Free Radic Biol Med (2007) 1.11
Molecular biology of androgen-independent prostate cancer: the role of the androgen receptor pathway. Clin Transl Oncol (2009) 1.10
Hypoxia increases androgen receptor activity in prostate cancer cells. Cancer Res (2006) 1.09
Thioredoxin peroxidase-1 (peroxiredoxin-1) is increased in thioredoxin-1 transfected cells and results in enhanced protection against apoptosis caused by hydrogen peroxide but not by other agents including dexamethasone, etoposide, and doxorubicin. Arch Biochem Biophys (2001) 1.09
JunD mediates androgen-induced oxidative stress in androgen dependent LNCaP human prostate cancer cells. Prostate (2008) 1.05
Studies on molecular mechanisms of growth inhibitory effects of thymoquinone against prostate cancer cells: role of reactive oxygen species. Exp Biol Med (Maywood) (2010) 1.00
Prx1 enhances androgen receptor function in prostate cancer cells by increasing receptor affinity to dihydrotestosterone. Mol Cancer Res (2009) 0.99
Thioredoxin and thioredoxin reductase as redox-sensitive molecular targets for cancer therapy. Curr Pharm Des (2007) 0.98
Genistein protects prostate cells against hydrogen peroxide-induced DNA damage and induces expression of genes involved in the defence against oxidative stress. Carcinogenesis (2006) 0.97
Tumor-specific cytotoxicity and apoptosis-inducing activity of berberines. Anticancer Res (2005) 0.96
Activation of glutathione peroxidase via Nrf1 mediates genistein's protection against oxidative endothelial cell injury. Biochem Biophys Res Commun (2006) 0.96
The CCAAT enhancer-binding protein (C/EBP)beta and Nrf1 interact to regulate dentin sialophosphoprotein (DSPP) gene expression during odontoblast differentiation. J Biol Chem (2004) 0.96
Advanced but not localized prostate cancer is associated with increased oxidative stress. J Urol (2007) 0.95
Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone. Endocr Relat Cancer (2009) 0.95
Thioredoxin and thioredoxin reductase influence estrogen receptor alpha-mediated gene expression in human breast cancer cells. J Mol Endocrinol (2009) 0.94
Modulation of GSH levels in ABCC1 expressing tumor cells triggers apoptosis through oxidative stress. Biochem Pharmacol (2007) 0.93
Upregulation of manganese superoxide dismutase (SOD2) is a common pathway for neuroendocrine differentiation in prostate cancer cells. Int J Cancer (2009) 0.93
Metallothionein is up-regulated under hypoxia and promotes the survival of human prostate cancer cells. Oncol Rep (2007) 0.91
Hormone resistance in prostate cancer. Cancer Metastasis Rev (1999) 0.91
Down regulation of PSA by C/EBPalpha is associated with loss of AR expression and inhibition of PSA promoter activity in the LNCaP cell line. BMC Cancer (2006) 0.89
Differential profile analysis of urinary cytokines in patients with overactive bladder. Int Urogynecol J (2011) 1.59
HIV-1 protease inhibitor induced oxidative stress suppresses glucose stimulated insulin release: protection with thymoquinone. Exp Biol Med (Maywood) (2009) 1.56
Cavernous neurotomy causes hypoxia and fibrosis in rat corpus cavernosum. J Androl (2003) 1.37
Interleukin-17 promotes formation and growth of prostate adenocarcinoma in mouse models. Cancer Res (2012) 1.26
Potential of mesenchymal stem cells in gene therapy approaches for inherited and acquired diseases. Expert Opin Biol Ther (2005) 1.24
Gene transfer of endothelial nitric oxide synthase partially restores nitric oxide synthesis and erectile function in streptozotocin diabetic rats. J Urol (2003) 1.22
Neoplastic reprogramming of patient-derived adipose stem cells by prostate cancer cell-associated exosomes. Stem Cells (2014) 1.20
Prognostic significance of cytoplasmic SOX9 in invasive ductal carcinoma and metastatic breast cancer. Exp Biol Med (Maywood) (2011) 1.15
Anticancer and chemosensitizing abilities of cycloviolacin 02 from Viola odorata and psyle cyclotides from Psychotria leptothyrsa. Biopolymers (2010) 1.13
Molecular characterization of exosome-like vesicles from breast cancer cells. BMC Cancer (2014) 1.11
The nuclear factor kappa-B signaling pathway as a therapeutic target against thyroid cancers. Thyroid (2012) 1.06
Adipose tissue-derived stem cell-seeded small intestinal submucosa for tunica albuginea grafting and reconstruction. Proc Natl Acad Sci U S A (2012) 1.04
Tumor-derived exosomes in oncogenic reprogramming and cancer progression. Cell Mol Life Sci (2014) 1.02
Studies on molecular mechanisms of growth inhibitory effects of thymoquinone against prostate cancer cells: role of reactive oxygen species. Exp Biol Med (Maywood) (2010) 1.00
Phosphorylation of p50 NF-kappaB at a single serine residue by DNA-dependent protein kinase is critical for VCAM-1 expression upon TNF treatment. J Biol Chem (2010) 0.99
MRP (ABCC) transporters-mediated efflux of anti-HIV drugs, saquinavir and zidovudine, from human endothelial cells. Exp Biol Med (Maywood) (2008) 0.99
Isolation, characterization, and bioactivity of cyclotides from the Micronesian plant Psychotria leptothyrsa. J Nat Prod (2010) 0.98
PDZK1 is a novel factor in breast cancer that is indirectly regulated by estrogen through IGF-1R and promotes estrogen-mediated growth. Mol Med (2013) 0.95
MicroRNA expression profiles in differentiated thyroid cancer, a review. Int J Clin Exp Med (2012) 0.95
Gene transfer of extracellular SOD to the penis reduces O2-* and improves erectile function in aged rats. Am J Physiol Heart Circ Physiol (2002) 0.93
Adenovirus-mediated inhibition of NF-kappaB confers chemo-sensitization and apoptosis in prostate cancer cells. Int J Oncol (2003) 0.92
Prospective dual role of mesenchymal stem cells in breast tumor microenvironment. Breast Cancer Res Treat (2012) 0.91
Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways. J Surg Res (2013) 0.89
Molecular analysis of cocaine-induced endothelial dysfunction: role of endothelin-1 and nitric oxide. Cardiovasc Toxicol (2008) 0.89
High circulating estrogens and selective expression of ERβ in prostate tumors of Americans: implications for racial disparity of prostate cancer. Carcinogenesis (2013) 0.88
BRAF mutation in papillary thyroid carcinoma. Int J Clin Exp Med (2012) 0.88
Cytoplasmic compartmentalization of SOX9 abrogates the growth arrest response of breast cancer cells that can be rescued by trichostatin A treatment. Cancer Biol Ther (2011) 0.88
Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer. Int J Oncol (2010) 0.87
PI3K/Akt-dependent transcriptional regulation and activation of BMP-2-Smad signaling by NF-kappaB in metastatic prostate cancer cells. Prostate (2009) 0.86
Suppression of clonogenic potential of human bone marrow mesenchymal stem cells by HIV type 1: putative role of HIV type 1 tat protein and inflammatory cytokines. AIDS Res Hum Retroviruses (2002) 0.85
Zidovudine (AZT) treatment suppresses granulocyte-monocyte colony stimulating factor receptor type alpha (GM-CSFR alpha) gene expression in murine bone marrow cells. Life Sci (2002) 0.84
Rosiglitazone reduces serum homocysteine levels, smooth muscle proliferation, and intimal hyperplasia in Sprague-Dawley rats fed a high methionine diet. Metabolism (2005) 0.84
Low-dose methylmercury-induced oxidative stress, cytotoxicity, and tau-hyperphosphorylation in human neuroblastoma (SH-SY5Y) cells. Environ Toxicol (2011) 0.83
The HIV-1 Tat protein enhances megakaryocytic commitment of K562 cells by facilitating CREB transcription factor coactivation by CBP. Exp Biol Med (Maywood) (2005) 0.82
Mesenchymal stem cell derived hematopoietic cells are permissive to HIV-1 infection. Retrovirology (2011) 0.82
Therapeutic effects of Nigella sativa on chronic HAART-induced hyperinsulinemia in rats. Can J Physiol Pharmacol (2009) 0.82
Reduced response of prostate cancer cells to TRAIL is modulated by NFkappaB-mediated inhibition of caspases and Bid activation. Int J Oncol (2002) 0.81
Potential role for the nuclear transcription factor NF-kappa B in the pathogenesis of ureteropelvic junction obstruction. J Endourol (2002) 0.81
Cycloviolacin O2 (CyO2) suppresses productive infection and augments the antiviral efficacy of nelfinavir in HIV-1 infected monocytic cells. Biopolymers (2013) 0.81
Specific increase in MDR1 mediated drug-efflux in human brain endothelial cells following co-exposure to HIV-1 and saquinavir. PLoS One (2013) 0.81
Imatinib mesylate (Gleevec) induces human corpus cavernosum relaxation by inhibiting receptor tyrosine kinases (RTKs): identification of new RTK targets. Urology (2013) 0.80
Functional androgen receptor confers sensitization of androgen-independent prostate cancer cells to anticancer therapy via caspase activation. Biochem Biophys Res Commun (2003) 0.80
Localization of peripheral dopamine D1 and D2 receptors in rat and human seminal vesicles. J Androl (2002) 0.79
Phosphorylated insulin like growth factor-I receptor expression and its clinico-pathological significance in histologic subtypes of human thyroid cancer. Exp Biol Med (Maywood) (2009) 0.78
Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavir. Biol Pharm Bull (2009) 0.78
In vivo proteomic analysis of cytokine expression in laser capture-microdissected urothelial cells of obstructed ureteropelvic junction procured by laparoscopic dismembered pyeloplasty. J Endourol (2003) 0.78
A systematic approach to document cyclotide distribution in plant species from genomic, transcriptomic, and peptidomic analysis. Biopolymers (2013) 0.77
Attenuation of low dose methylmercury and glutamate induced-cytotoxicity and tau phosphorylation by an N-methyl-D-aspartate antagonist in human neuroblastoma (SHSY5Y) cells. Environ Toxicol (2011) 0.76
Methods in assessing homocysteine metabolism. Metab Syndr Relat Disord (2003) 0.76
Expression of melanocortin receptors in human prostate cancer cell lines: MC2R activation by ACTH increases prostate cancer cell proliferation. Int J Oncol (2012) 0.76
Management of erectile function by penile purinergic p2 receptors in the diabetic rat. J Urol (2009) 0.75
Upregulation of HTLV-1 and HTLV-2 expression by HIV-1 in vitro. J Med Virol (2008) 0.75
Neuronal stem cells biology and plasticity. Cancer Invest (2003) 0.75
Novel "breath figure"-based synthetic PLGA matrices for in vitro modeling of mammary morphogenesis and assessing chemotherapeutic response. Adv Healthc Mater (2013) 0.75
Recyclable single-stranded DNA template for synthesis of siRNAs. BMB Rep (2010) 0.75